Some studies have found that TAMs promote tumor progression in CRC patients; CD68+ macrophages are used as a marker of progression, and CD163+ macrophages are associated with early local recurrence and reduced survival times [49, 50]. Here, CD163 is linked to colorectal carcinoma.